Latest Capital Raising News

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Simble Solutions Limited reported a 21.3% revenue decline and a $646,578 net loss for H1 2025, while raising $807,375 to fund strategic growth in renewable energy and AI integration.

Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.

Identitii Limited reported a modest 4% revenue increase to $777,542 for FY25, yet its net loss expanded by 8% to $3.82 million, driven by lower investment gains. The company strengthened its cash position through successful capital raising and ongoing cost reductions.

Pure Hydrogen Corporation has had its trading suspension lifted immediately following a capital raising announcement, signaling renewed market activity for the energy company.

Pure Hydrogen Corporation has raised A$1 million through a share placement with attaching options, aiming to accelerate its clean energy projects across Australia and the US.

Income Asset Management Group reported a robust FY2025 with significant revenue and client growth, alongside strategic cost reductions and a new product launch planned for FY26.

Income Asset Management Group reported a 22% revenue increase and a significant reduction in net loss for FY25, underpinned by strategic cost cuts, debt repayment, and governance enhancements. The Group also launched a new managed account product and announced key board changes.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Energy Technologies Limited reported a $11 million net loss for FY2025, reflecting a strategic pivot and ongoing capital challenges. Despite a 37% revenue drop, management highlights operational resilience and plans to stabilise through capital management.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

Alternative Investment Trust (ASX, AIQ) reported a robust half-year profit increase of 183%, driven by strong gains in its Warana-managed portfolio. The Trust also announced a significant $44.6 million rights issue to fund further investments.